Sponsor: SWOG
Sponsor Study ID: S2303
Study Title: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
CTO #: 104136
NCT Number: NCT06203600
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Esophagus
Study Objectives: To compare health-related quality of life (HRQOL) by treatment arm at 8 weeks after randomization, measured using the Functional Assessment of Cancer Therapy Gastric (FACT-Ga) Trial Outcome Index.